RNA Interference (RNAi) - Global Strategic Business Report

The global market for RNA Interference (RNAi) is estimated at US$99.4 Billion in 2023 and is projected to reach US$206.7 Billion by 2030, growing at a CAGR of 11.0% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

RNAi technology is a growth driver in both medical and agricultural fields, propelled by advancements such as improved RNAi delivery mechanisms using lipid nanoparticles, development of stable RNAi compounds, and enhanced precision in gene targeting. Its integration with other genomic tools like CRISPR enhances its utility in genomic research. Additionally, the rising demand for personalized medicine, where RNAi`s specificity can tailor treatments to individual genetic profiles, highlights its potential in custom therapeutic strategies. In agriculture, RNAi`s application in developing crops with increased yield, pest resistance, and improved nutritional profiles demonstrates its contribution to sustainable practices. Regulatory approvals for RNAi-based therapeutics and substantial funding from both public and private sectors are accelerating the adoption and development of RNAi technologies, promising significant advancements in gene therapy, drug development, and environmental sustainability.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Drug Discovery & Development Application segment, which is expected to reach US$118.1 Billion by 2030 with a CAGR of a 16.4%. The Therapeutics Application segment is also set to grow at 5.7% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, estimated at $25.6 Billion in 2023, and China, forecasted to grow at an impressive 17.3% CAGR to reach $59.5 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global RNA Interference (RNAi) Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global RNA Interference (RNAi) Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global RNA Interference (RNAi) Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of major players such as Alnylam Pharmaceuticals, Inc., Benitec BioPharma, Ionis Pharmaceuticals, Inc., and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Select Competitors (Total 12 Featured):

• Alnylam Pharmaceuticals, Inc.
• Benitec BioPharma
• Ionis Pharmaceuticals, Inc.
• Ionis Pharmaceuticals, Inc.
• Qiagen, Inc.
• Quark Pharmaceuticals, Inc.
• Silence Therapeutics PLC